Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb sat down with Proactive at the Biotech Showcase 2020 in San Francisco. Emalfarb talks about how there's a lot of things the government can do to speed the development of new biologics to the market. Namely, by offering a simliar orphan disease/fast-track status to platforms like Dyadic's C1 platform that could dramatically lower the cost and time to manufacture drugs, that could inevitably help more people.
Dyadic CEO remarks on steps the federal gov't can take to speed along drug manufacturing
Quick facts: Dyadic International Inc
Price: 9.11 USD
Market Cap: $250.24 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE